135 related articles for article (PubMed ID: 1412199)
1. Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger's disease).
Choudhury NA; Pietraszek MH; Hachiya T; Baba S; Sakaguchi S; Takada Y; Takada A
Thromb Res; 1992 May; 66(4):321-9. PubMed ID: 1412199
[TBL] [Abstract][Full Text] [Related]
2. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis.
Nguyen G; Horellou MH; Kruithof EK; Conard J; Samama MM
Blood; 1988 Aug; 72(2):601-5. PubMed ID: 3135860
[TBL] [Abstract][Full Text] [Related]
3. The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stasis.
Falkon L; Garí M; Borrell M; Fontcuberta J
Blood Coagul Fibrinolysis; 1992 Feb; 3(1):33-8. PubMed ID: 1623118
[TBL] [Abstract][Full Text] [Related]
4. [Hypofibrinolysis after venous occlusion in patients treated with long-term hemodialysis].
Opatrný K; Vít L; Opatrná S; Sulková S; Bodláková B
Cas Lek Cesk; 1994 May; 133(11):346-9. PubMed ID: 8004664
[TBL] [Abstract][Full Text] [Related]
5. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
6. Tissue-type plasminogen activator, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation.
Fukao H; Ueshima S; Okada K; Yamamoto K; Matsuo T; Matsuo O
Thromb Res; 1992 Oct; 68(1):57-65. PubMed ID: 1280377
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical properties in the patients with Buerger's disease--possible role of plasminogen activator inhibitor-1 for preservation of vessel wall architecture.
Sato T; Tamai H; Kobayashi M; Yamamoto K; Komori K
Cardiovasc Pathol; 2011; 20(5):266-71. PubMed ID: 20708412
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
Casslén B; Bossmar T; Lecander I; Astedt B
Eur J Cancer; 1994; 30A(9):1302-9. PubMed ID: 7999418
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation.
Kruithof EK; Nicolosa G; Bachmann F
Blood; 1987 Nov; 70(5):1645-53. PubMed ID: 3117137
[TBL] [Abstract][Full Text] [Related]
10. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state.
Patrassi GM; Sartori MT; Viero ML; Scarano L; Boscaro M; Girolami A
Blood Coagul Fibrinolysis; 1992 Dec; 3(6):789-93. PubMed ID: 1489900
[TBL] [Abstract][Full Text] [Related]
11. Reproducibility of fibrinolytic response to venous occlusion in healthy subjects.
Stegnar M; Mavri A
Thromb Haemost; 1995 Mar; 73(3):453-7. PubMed ID: 7667828
[TBL] [Abstract][Full Text] [Related]
12. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states.
Niwano H; Takahashi H; Tatewaki W; Wada K; Seki Y; Shibata A
Blood Coagul Fibrinolysis; 1992 Aug; 3(4):389-93. PubMed ID: 1420814
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolysis in hypertriglyceridaemic subjects in response to venous occlusion.
Avellone G; Di Garbo V; Cordova R; Raneli G; De Simone R; Bompiani GD
Blood Coagul Fibrinolysis; 1993 Jun; 4(3):429-33. PubMed ID: 8329569
[TBL] [Abstract][Full Text] [Related]
14. Assessment of plasma prothrombotic factors in patients with Buerger's disease.
Hus I; Sokolowska B; Walter-Croneck A; Chrapko M; Nowaczynska A; Dmoszynska A
Blood Coagul Fibrinolysis; 2013 Mar; 24(2):133-9. PubMed ID: 23358197
[TBL] [Abstract][Full Text] [Related]
15. The pathogenesis of accelerated fibrinolysis in hepatosplenic schistosomiasis.
Omran SA; Madkour BA; Essawy FM; Toima SM; el Kaliouby AH; Shams el Din AA
Blood Coagul Fibrinolysis; 1992 Dec; 3(6):819-22. PubMed ID: 1489902
[TBL] [Abstract][Full Text] [Related]
16. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
[TBL] [Abstract][Full Text] [Related]
17. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
20. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism.
Grimaudo V; Bachmann F; Hauert J; Christe MA; Kruithof EK
Thromb Haemost; 1992 Apr; 67(4):397-401. PubMed ID: 1631786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
